Launch Represents Significant Step to Broader Commercialization
Myriad Genetics, Inc.(NASDAQ MYGN), a leader in molecular individual testing and precision medicine, has announced the limited launch of its Precise MRD ™(molecular residual disease) test with select oncology practices for cases diagnosed with breast cancer. The introduction marks a significant advancement in AI in healthcare and cancer diagnostics, supporting earlier discovery and further individualized treatment strategies for oncology cases.
The Precise MRD test is a tumor-informed circulating tumor DNA(ctDNA) assay developed to enable longitudinal monitoring throughout cancer treatment. By using whole-genome sequencing, the test creates an individualized molecular profile for each case, allowing ultrasensitive discovery of ctDNA in situations as low as one part per million. This position of perfection provides clinicians with earlier insight into residual complaints that may not be visible through conventional imaging or microscopic examination.
Brian Donnelly, Chief Commercial Officer at Myriad Genetics, described the limited release as an important corner in cancer care. “ By detecting ctDNA in extremely low situations, the Precise MRD test will enable earlier insight and more informed treatment opinions,” he stated. The launch also reflects Myriad’s strategic focus on disciplined protection and delivering innovative medical diagnostics within a defined commercial timeline.
Minimal residual disease testing has become increasingly important in oncology as healthcare providers seek further visionary, data-driven approaches to managing cancer. AI in healthcare, genomic analytics, and advanced sequencing technologies are reshaping how clinicians cover complaint progression and tailor therapies to individual cases. The Precise MRD test supports this precision drug model by offering real-time molecular perception that can guide remedial opinions.
Health Technology Insights: https://healthtechnologyinsights.com/russias-cancer-vaccine-is-a-new-breakthrough-in-health-technology/
Derrick S. Haslem, MD, ACMO of Specialty Care at Intermountain Health in the Desert Region, highlighted the clinical value of such advancements. He noted that molecular residual disease testing enables physicians to detect cancer cells that persist after treatment but remain undetectable through standard diagnostic methods, strengthening personalized cancer care strategies.
In its initial phase, the Precise MRD test will be available to select community oncologists treating bone cancer cases, with no cap on sharing individualities. A broader commercial rollout across the United States is planned later this year. Sucharu Prakash, MD, Director of Quality Services for Texas Oncology, emphasized the practical impact on pastoral healthcare settings, where cases frequently travel long distances for imaging and follow-up care. According to Dr. Prakash, the test offers precious insight into whether treatment is working and supports more informed opinions about remedy intensity and duration.
By integrating precision diagnostics, genomic sequencing, and AI- enabled analytics, Myriad Genetics continues to expand its role in transforming cancer monitoring. The launch of Precise MRD underscores the growing importance of molecular testing in improving patient issues and advancing modern oncology care.
Health Technology Insights: https://healthtechnologyinsights.com/the-new-era-of-gene-editing-what-crispr-means-for-patients/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
